Airato develops AIVOT, an AI engine that gives every community hospital radiation oncology department a clinically validated starting point for IMRT treatment planning.
Yuto Kimura spent two years as a medical physics researcher at Tohoku University Hospital in Sendai, working alongside the radiation oncology department. He watched dosimetrists re-optimize the same head-and-neck IMRT plan three times over four days — not because of errors, but because the initial manual optimization consistently produced suboptimal OAR sparing that the attending physician flagged at review. A patient's treatment start was delayed by nearly a week.
The bottleneck was not machine time or physician availability. It was the absence of a clinically validated starting point. Every plan began from scratch, and quality depended entirely on the individual dosimetrist's experience with that specific treatment site, on that specific day.
Yuto and co-founder Riku Nakamura trained a dose prediction model on 800 approved Tohoku University Hospital IMRT plans and tested it on a prospective set of 30 cases. Plans initialized with the AI baseline required an average of 40 minutes of dosimetrist refinement versus 3.2 hours from scratch. Twenty-eight of 30 passed physician review on first submission.
That result became the foundation for Airato. The company now develops AIVOT as a DICOM-RT native service focused on community hospital radiation oncology departments — where dosimetrist capacity is most constrained, and the benefit of a validated starting point is largest. Airato is engaged with five pilot hospital departments in Japan and entering the US market.
Give every radiation therapy patient access to consistently high-quality IMRT planning, regardless of which hospital they are treated at.
Every capability in AIVOT is validated against physician-approved clinical data before it reaches a production deployment.
AIVOT initializes and scores — it does not approve. The dosimetrist and physician retain full control over every plan.
Airato operates within the DICOM-RT standard that your TPS already supports. No middleware, no vendor contracts beyond AIVOT.
Academic centers have large in-house engineering teams. Community hospitals need a ready-to-deploy solution — that is our focus.
Planning time is a proxy. Airato tracks conformity index, OAR dose adherence, and first-pass physician approval rates across every department.
Airato is supported by institutional investors who share our focus on evidence-based healthcare AI at the point of clinical need. We do not disclose investment amounts or dates.
We work with radiation oncology departments at community and regional hospitals. If your team is carrying a planning backlog or evaluating options for dosimetrist capacity, we can walk through AIVOT with your own treatment site data — no commitment required to schedule a session.